Dhcp Letter 1.jpg (Image 01)
The text provides important prescribing information regarding the temporary importation of 0.9% Sodium Chloride Injection from Shanghai, China by Baxter to address drug shortages. It states that the FDA has not approved these products manufactured by Baxter's Shanghai facility. Healthcare professionals will receive additional letters for other imported products and are advised to inspect the packaging for any defects before administration. The imported products have primary container labels written in Chinese, containing essential information in English such as the active pharmaceutical ingredient, concentration, volume, and product code. Please note that Baxter is the only entity authorized by the FDA to import or distribute these products in the United States during this temporary period.*